reports
A double requalification allows CHINA RESOURCES PHARMACEUTICAL GROUP t...
CHINA RESOURCES PHARMACEUTICAL GROUP (HK), a company active in the Pharmaceuticals industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation is now 4 out of 4 stars while its market behaviour can be considered as defensive. theScreener believes that the gain of a star(s) and an improvement in the market risk perception allows upgrading the general evaluation to Slightly Positive. As of the analysis date January 4, 2022, the closin...
China Resources Pharmaceutical Group Limited: 1 director maiden bought
A director at China Resources Pharmaceutical Group Limited maiden bought 300,000 shares at 4.588HKD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
- Jay Lee
Morningstar | China to audit 77 drugmakers, government likely to speed...
On the morning of June 4 2019, China’s Ministry of Finance, or MOF, announced it and the Medical Insurance Administration will jointly audit the accounting practices of 77 drugmakers during June and July. The stocks of Chinese drugmakers have fallen sharply following the news as the market braces for more policy uncertainty. Among our coverage, the list includes narrow-moat Shanghai Pharmaceuticals, CR Sanjiu (a listed subsidiary of narrow-moat CR Pharmaceuticals), and one unlisted subsidiar...
- Jay Lee
China to audit 77 drugmakers, government likely to speed up pricing re...
On the morning of June 4 2019, China’s Ministry of Finance, or MOF, announced it and the Medical Insurance Administration will jointly audit the accounting practices of 77 drugmakers during June and July. The stocks of Chinese drugmakers have fallen sharply following the news as the market braces for more policy uncertainty. Among our coverage, the list includes narrow-moat Shanghai Pharmaceuticals, CR Sanjiu (a listed subsidiary of narrow-moat CR Pharmaceuticals), and one unlisted subsidiary...
- Jay Lee
Morningstar | CR Pharma's Full-Year Results in Line, but Less Impressi...
Narrow-moat CR Pharma reported 2018 earnings that were in line with expectations, but showed slower growth and lower margins than in the first half. We have lowered our fair value estimate to HKD 12.50 per share from HKD 13.20 due to minor tweaks in our margin assumptions. Full-year results were largely in line with our expectations, with revenue growth of 11.9% and operating margins of 5.4% (when calculated using cost of sales, selling, general, and administrative, and other expenses). Despite...
- Jay Lee
Morningstar | CR Pharma's Full-Year Results in Line, but Less Impressi...
Narrow-moat CR Pharma reported 2018 earnings that were in line with expectations, but showed slower growth and lower margins than in the first half. We have lowered our fair value estimate to HKD 12.50 per share from HKD 13.20 due to minor tweaks in our margin assumptions. Full-year results were largely in line with our expectations, with revenue growth of 11.9% and operating margins of 5.4% (when calculated using cost of sales, selling, general, and administrative, and other expenses). Despite...
- Jay Lee
CR Pharma's Full-Year Results in Line, but Less Impressive Than 1H; De...
Narrow-moat CR Pharma reported 2018 earnings that were in line with expectations, but showed slower growth and lower margins than in the first half. We have lowered our fair value estimate to HKD 12.50 per share from HKD 13.20 due to minor tweaks in our margin assumptions. Full-year results were largely in line with our expectations, with revenue growth of 11.9% and operating margins of 5.4% (when calculated using cost of sales, selling, general, and administrative, and other expenses). Despite ...
- Jay Lee
CR Pharma Is a Well-Branded Pharmaceutical Conglomerate in China
On March 11, Shanghai Fudan Zhangjiang Bio-Pharmaceutical, or FD-ZJ, announced plans to issue A shares on the Sci-Tech Innovation Board at the Shanghai Stock Exchange. This announcement caused FD-ZJ’s share price to rally 26% and galvanized the entire Chinese healthcare sector. Narrow-moat Shanghai Pharmaceuticals Holding owns 23% of FD-ZJ; SPH’s A shares rallied 10%, although its H shares experienced a modest increase of 4%. While we believe SPH’s H shares are undervalued, this listing an...
- Jay Lee
Morningstar | Fudan Zhangjiang Applies for Listing in China; Chinese H...
On March 11, Shanghai Fudan Zhangjiang Bio-Pharmaceutical, or FD-ZJ, announced plans to issue A shares on the Sci-Tech Innovation Board at the Shanghai Stock Exchange. This announcement caused FD-ZJ’s share price to rally 26% and galvanized the entire Chinese healthcare sector. Narrow-moat Shanghai Pharmaceuticals Holding owns 23% of FD-ZJ; SPH’s A shares rallied 10%, although its H shares experienced a modest increase of 4%. While we believe SPH’s H shares are undervalued, this listing an...
- Jay Lee
Fudan Zhangjiang Applies for Listing in China; Chinese Healthcare Stoc...
On March 11, Shanghai Fudan Zhangjiang Bio-Pharmaceutical, or FD-ZJ, announced plans to issue A shares on the Sci-Tech Innovation Board at the Shanghai Stock Exchange. This announcement caused FD-ZJ’s share price to rally 26% and galvanized the entire Chinese healthcare sector. Narrow-moat Shanghai Pharmaceuticals Holding owns 23% of FD-ZJ; SPH’s A shares rallied 10%, although its H shares experienced a modest increase of 4%. While we believe SPH’s H shares are undervalued, this listing an...
- Jay Lee
Morningstar | Initiating Coverage of CR Pharma With Narrow Moat Rating...
We initiate coverage on China Resources Pharmaceutical Group with a narrow moat rating and a fair value estimate of HKD 13.20 per share. This implies a 2018 adjusted P/E of 20.5 times and enterprise value/EBITDA of 7.2 times. The market is currently pricing CR Pharma at a 9% discount to our fair value estimate. CR Pharma is a top-three drug distributor in China and vertically integrated with a diversified drugmaking segment and a retail distribution franchise. The large scale of its distributio...
- Jay Lee
Morningstar | Initiating Coverage of CR Pharma With Narrow Moat Rating...
We initiate coverage on China Resources Pharmaceutical Group with a narrow moat rating and a fair value estimate of HKD 13.20 per share. This implies a 2018 adjusted P/E of 20.5 times and enterprise value/EBITDA of 7.2 times. The market is currently pricing CR Pharma at a 9% discount to our fair value estimate. CR Pharma is a top-three drug distributor in China and vertically integrated with a diversified drugmaking segment and a retail distribution franchise. The large scale of its distributio...
- Jay Lee
Initiating Coverage of CR Pharma With Narrow Moat Rating and HKD 13.20...
We initiate coverage on China Resources Pharmaceutical Group with a narrow moat rating and a fair value estimate of HKD 13.20 per share. This implies a 2018 adjusted P/E of 20.5 times and enterprise value/EBITDA of 7.2 times. The market is currently pricing CR Pharma at a 9% discount to our fair value estimate. CR Pharma is a top-three drug distributor in China and vertically integrated with a diversified drugmaking segment and a retail distribution franchise. The large scale of its distribution...
- Jay Lee
A Well-Branded Pharmaceutical Conglomerate With Distribution, Manufact...
CR Pharma is a conglomerate that operates manufacturing, distribution, and retail pharmacy segments. Chinese healthcare industries have grown faster than GDP, and will continue to do so due to aging demographics, increased urbanization, a larger middle class, and rising disease rates.Distribution contributes an estimated 50% of consolidated operating profit as of 2017, but close to two thirds of operating profit attributable to owners. As an industry, distribution is relatively defensive compare...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.